On the basis of this study, APL patients must be considered at lower risk of IFI if treated with differentiation-inducing agents. Taking the substantial cost of prophylactic antifungal treatment and the possible side effects, interaction between azoles and drugs active for the treatment of APL into account, a mould active antifungal prophylaxis could be omitted in APL patients at the first induction phase of their treatment.
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry / Pagano, L., Stamouli, M., Tumbarello, M., Verga, L., Candoni, A., Cattaneo, C., Nadali, G., Mitra, M.e., Mancini, V., Nosari, A., Garzia, M.g., Delia, M., Storti, S., Spadea, A., Caramatti, C., Perriello, V., Sanna, M., Vacca, A., De Paolis, M.r., Potenza, L., et al.. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 170:(2015), pp. 434-439. [doi: 10.1111/bjh.13308]
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry.
FANCI, ROSA;
2015
Abstract
On the basis of this study, APL patients must be considered at lower risk of IFI if treated with differentiation-inducing agents. Taking the substantial cost of prophylactic antifungal treatment and the possible side effects, interaction between azoles and drugs active for the treatment of APL into account, a mould active antifungal prophylaxis could be omitted in APL patients at the first induction phase of their treatment.
| File | Dimensione | Formato | |
|---|---|---|---|
|
British_Journal_of_Haematology 2015.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
80.55 kB
Formato
Adobe PDF
|
80.55 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
